The effects of synthetic 19-norprogestins on osteoblastic cell function are mediated by their non-phenolic reduced metabolites.

The key role of estrogens on osteoblastic cell function is well documented; however, the role of progesterone (P) and synthetic progestins remains controversial. While several reports indicate that P has no significant effects on bone cells, a number of clinical studies have shown that 19-norprogestins restore postmenopausal bone loss. The mechanisms by which 19-norprogestins induce estrogen-like effects on bone cells are not fully understood. To assess whether the actions of 19-norprogestins on osteoblasts are mediated by their non-phenolic metabolites, we studied the effects of norethisterone (NET), levonorgestrel (LNG), and two of their A-ring reduced derivatives upon cell proliferation and differentiation in neonatal rat osteoblasts. Osteoblast function was assessed by determining cell DNA, cell-associated osteocalcin and calcium content, alkaline phosphatase activity, and mineral deposition. P failed to induce changes on osteoblasts, while NET and LNG exerted a number of actions. The most striking finding was that the 3beta,5alpha- and 3alpha,5alpha-tetrahydro derivatives of NET and LNG induced osteoblast proliferation and differentiation with higher potency than those exerted by their parent compounds, mimicking the effects of estradiol. Interestingly, osteoblast differentiation and mineral deposition induced by NET and LNG were abolished by finasteride, a 5alpha-reductases inhibitor, while the potent effect on osteoblast proliferation induced by progestin derivatives was abolished by a steroidal antiestrogen. Results demonstrate that A-ring reduced derivatives of NET and LNG exhibit intrinsic estrogen-like potency on rat osteoblasts, offering a plausible explanation for the mechanism of action of 19-norprogestins in bone restoration in postmenopausal women and providing new insights for hormone replacement therapy research.

Enhanced formation of non-phenolic androgen metabolites with intrinsic oestrogen-like gene transactivation potency in human breast cancer cells: a distinctive metabolic pattern.

Breast cancer is a sex steroid hormone-dependent malignant neoplasia. The role of oestradiol in this malignancy has been well documented; however, the involvement of androgens has remained controversial. To determine the role of non-phenolic androgen metabolites in human breast cancer, we studied the metabolism of [(14)C] testosterone and [(14)C] androstenedione in oestrogen-dependent MCF-7 cells and non-oestrogen-dependent MDA-MB 231 cells, at different substrate concentrations (1-10 muM) and time periods (30 min-48 h). Cultured non-oestrogen-dependent HeLa and yeast cells served as controls. Metabolites were identified and quantified by reverse isotope dilution. A distinctive pattern of androgen metabolism was identified in MCF-7 cells, being the 5alpha-androstane-3alpha,17beta-diol (3alpha,5alpha-diol) and its 3beta epimer (3beta,5alpha-diol), the major conversion products of testosterone (48.3%), with 5alpha-dihydrotestosterone as intermediary. The formation of 3alpha,5alpha-diol and 3beta,5alpha-diol (diols) was substrate concentration- and time-dependent, and abolished by finasteride. In contrast, very little of any diol formation was observed in MDA-MB 231, HeLa and yeast cell incubations. Additional enzyme gene expression studies revealed an overexpression of 5alpha-steroid reductase type-1 in MCF-7 cells, as compared with MDA-MB 231 cells. The oestrogen-like activities of diols were assessed in HeLa cells co-transfected with expression vectors for alpha or beta subtypes of the human oestrogen receptor (hER) genes and for an oestrogen-responsive reporter gene. The results show that 3beta, 5alpha-diol and to a lesser extent 3alpha,5alpha-diol bind with high relative affinity to hERalpha and hERbeta. Both diols induced hER-mediated reporter gene transactivation in a dose-response manner, similar to that induced by oestradiol, though with lower potency, an effect that was abolished by ICI-182 780. Furthermore, 3beta,5alpha-diol and to lesser extent 3alpha,5alpha-diol induced MCF-7 cell proliferation. The overall results demonstrated that MCF-7 cells exhibit enhanced expression and activity of androgen-metabolising enzymes, leading to rapid and large diol formation, and provide evidence that these androgen metabolites exert a potent oestrogen-agonistic effect, at genomic level, in oestrogen-dependent breast cancer cells. The data suggest that diols may act as in situ intracrine factors in breast cancer and that its formation can be pharmacologically inhibited.

Synthetic 19-nortestosterone derivatives as estrogen receptor alpha subtype-selective ligands induce similar receptor conformational changes and steroid receptor coactivator recruitment than natural estrogens.

The binding of estradiol (E(2)) to estrogen receptors (ER) is followed by conformational changes resulting in coactivator or corepressor recruitment that influences gene transcription. A series of synthetic A-ring reduced 19-nortestosterone-derived progestins has the capacity to selectively bind and activate transcription through the ERalpha. Herein, the molecular mechanisms involved in ER subtype-selective interactions of these compounds as assessed by their effects upon both ERalpha and ERbeta structural conformation and their ability to induce recruitment of steroid receptor coactivator-1 (SRC-1) to ERalpha were investigated. The results demonstrated that all synthetic A-ring 3beta,5alpha-tetrahydro-reduced derivatives of 19-nortestosterone induced an ERalpha trypsin digestion pattern similar to that seen with E(2), without effects upon ERbeta. In addition, these compounds had the ability to recruit SRC-1 to the ligand-binding domain of ERalpha similar to E(2). Our data indicate that A-ring 3beta,5alpha-tetrahydro-reduced 19-nortestosterone-derived progestins behave as selective ERalpha agonists with ligand-receptor structural and functional responses similar to those induced with natural E(2).

The intrinsic transcriptional estrogenic activity of a non-phenolic derivative of levonorgestrel is mediated via the estrogen receptor-alpha.

Levonorgestrel (LNG), a 19-nor-testosterone derivative, is widely used in contraceptive formulations. This compound does not bind to the estrogen receptor (ER), but it shows estrogen-like effects under in vivo and in vitro conditions. The estrogenicity of LNG may be attributed to its bio-transformation into non-phenolic metabolites. In this study, the ability of A-ring reduced LNG metabolites to activate transcription via an estrogenic mechanism of action, including differences between ER alpha and ER beta subtypes, were investigated. Transactivation assays were performed in HeLa cells transfected with expression vectors for ER alpha and ER beta and an estrogen-responsive reporter gene. Cells were also transfected with expression vectors for both progesterone receptor (PR) isoforms (A or B). As expected, the tetrahydro derivatives of LNG (3 alpha,5 alpha- and 3 beta,5 alpha-LNG) showed significantly lower PR-mediated transcriptional activities through both isoforms when compared with progesterone (P(4)) and LNG. In contrast, the 3 beta,5 alpha-tetrahydro derivative resulted in a significant activation of estrogen-dependent gene transcription. This effect was selectively confined to the ER alpha, since little if any activity could be observed with the ER beta and no antagonistic activities were demonstrated. This study provides structural and molecular clues for the well documented in vitro and in vivo intrinsic estrogenicity of 19-nor-testosterone-derived progestins and ligand requirements for ER alpha recognition.

Comparative evaluation of androgen and progesterone receptor transcription selectivity indices of 19-nortestosterone-derived progestins.

Synthetic 19-nortestosterone-derived progestins show affinity for the androgen receptor (AR) and retain varying degrees of androgenic activity. In this study, AR- and progesterone receptor (PR)-dependent transcriptional activation induced by norethisterone (NET), levonorgestrel (LNG) and gestodene (GSD), and their 5alpha-reduced derivatives, including limited trypsin digestion of AR in the presence of natural and synthetic progestins were investigated. The results confirmed the progestogenic activity of the three 19-nortestosterone derivatives, which decreases after reduction of the 4-ene-double bound. These compounds were able to activate AR-dependent reporter gene expression, LNG and GSD being the stronger activators. 5alpha-Reduction of LNG and GSD did not change their androgenic transcriptional activity; however, the activation of AR by 5alpha-NET was four-fold higher than NET. The highest selectivity transcriptional index, as a measure of progestogenicity versus androgenicity, was obtained for NET. The 5alpha-reduced derivatives had values significantly lower than those of their parent compounds. Non-reduced and 5alpha-reduced 19-nortestosterone progestins induced virtually identical proteolysis fragmentation patterns of the AR to those observed with DHT.

Vasodilating effect of norethisterone and its 5 alpha metabolites: a novel nongenomic action.

Estrogens are generally administered in hormone replacement therapy in combination with synthetic progestins. Studies of cardiovascular risk factors in postmenopausal women have shown a variety of responses according to the molecular structure of the progestin used in hormone replacement therapy schemes. The present study sets out to determine the vasoactive effects of norethisterone and its 5alpha-dihydro (5alpha-norethisterone) and -tetrahydro (3alpha,5alpha-norethisterone and 3beta,5alpha-norethisterone) metabolites in isolated precontracted rat thoracic aorta. The addition of norethisterone and 3alpha,5alpha-norethisterone in rat aorta exhibited a potent, concentration-response inhibition of noradrenaline-induced contraction, while 5alpha- and 3beta,5alpha-norethisterone had very little, if any, vasorelaxing effect. Relaxation to norethisterone and 3alpha,5alpha-norethisterone had very rapid time-courses and it was neither affected by the absence of endothelium nor by the inhibitor of nitric oxide synthase, Nomega-nitro-L-arginine methyl ester (L-NAME). The addition of specific anti-androgen, anti-progestin and anti-estrogen compounds and protein synthesis inhibitors did not preclude the vasorelaxing effect of norethisterone and its 3alpha,5alpha-reduced metabolite. The results strongly suggest that these effects are not mediated by nuclear sex steroid hormone receptors. The overall data document a novel nongenomic endothelium-independent vasorelaxing action of a 19-nor synthetic progestin and one of its A-ring-reduced derivatives.

Neonatal rat osteoblasts bioconvert testosterone to non-phenolic metabolites with estrogen-like effects on bone cell proliferation and differentiation.

Testosterone (T) restores bone mass loss in postmenopausal women and osteoporotic men mainly through its bioconversion to estradiol (E2). In target tissues, T is also biotransformed to the A-ring-reduced metabolites 3α,5α-androstanediol (3α,5α-diol) and 3ß,5α-androstanediol (3ß,5α-diol), which are potent estrogen receptor (ER) agonists; however, their biological role in bone has not been completely elucidated. To assess if osteoblasts bioconvert T to 3α,5α-diol and to 3ß,5α-diol, we studied in cultured neonatal rat osteoblasts the metabolism of [14C]-labeled T. In addition, the intrinsic estrogenic potency of diols on cell proliferation and differentiation in neonatal calvarial rat osteoblasts was also investigated. Osteoblast function was assessed by determining cell DNA, cell-associated osteocalcin, and calcium content, as well as alkaline phosphatase activity and Alp1 gene expression. The results demonstrated that diols were the major bioconversion products of T, with dihydrotestosterone being an obligatory intermediary, thus demonstrating in the rat osteoblasts the activities of 5α-steroid reductase and 3α- and 3ß-hydroxysteroid dehydrogenases. The most important finding was that 3ß,5α- and 3α,5α-diols induced osteoblast proliferation and differentiation, mimicking the effect of E2. The observation that osteoblast differentiation induced by diols was abolished by the presence of the antiestrogen ICI 182,780, but not by the antiandrogen 2-hydroxyflutamide, suggests that diols effects are mediated through an ER mechanism. The osteoblast capability to bioconvert T into diols with intrinsic estrogen-like potency offers new insights to understand the mechanism of action of T on bone cells and provides new avenues for hormone replacement therapy to maintain bone mass density.

Connexin 36 is expressed in beta and connexins 26 and 32 in acinar cells at the end of the secondary transition of mouse pancreatic development and increase during fetal and perinatal life.

To identify when during fetal development connexins (Cxs) 26 (Cx26) 32 (Cx32), and 36 (Cx36) begin to be expressed, as well as to characterize their spatial distribution, real time polymerase chain reaction and immunolabeling studies were performed. Total RNA from mouse pancreases at 13 and 18 days postcoitum (dpc) and 3 days postpartum (dpp) was analyzed. In addition, pancreatic sections of mouse at 13, 14, 15, 16, 18 dpc and 3 dpp and of rat at term were double labeled with either anti-insulin or anti-α-amylase and anti-Cx26 or -Cx32 or -Cx36 antibodies and studied with confocal microscopy. From day 13 dpc, Cxs 26, 32, and 36 transcripts were identified and their levels increased with age. At 13-14 dpc, Cxs 26 and 32 were localized in few acinar cells, whereas Cx36 was distributed in small beta cell clumps. From day 14 dpc onwards, the number of labeled cells and relative immunofluorescent reactivity of all three Cxs at junctional membranes of the respective cell types increased. Cxs 26 and 32 colocalized in fetal acinar cells. In rat pancreas at term, a similar connexin distribution was found. Relative Cxs levels evaluated by immunoblotting also increased (two-fold) in pancreas homogenates from day 18 dpc to 3 dpp. The early cell specific, wide distribution, and age dependent expression of Cxs 26, 32, and 36 during fetal pancreas ontogeny suggests their possible involvement in pancreas differentiation and prenatal maturation.

Bioconversion of norethisterone, a progesterone receptor agonist into estrogen receptor agonists in osteoblastic cells.

A number of clinical studies have demonstrated that norethisterone (NET), a potent synthetic progestin, restores postmenopausal bone loss, although its mode of action on bone cells is not fully understood, while the effect of naturally occurring progesterone in bone has remained controversial. A recent report claims that the potent effects of NET on osteoblastic cell proliferation and differentiation, mimicking the action of estrogens, are mediated by non-phenolic NET derivatives. To determine whether osteoblasts possess the enzymes required to bioconvert a progesterone receptor (PR) agonist into A-ring reduced metabolites with affinity to bind estrogen receptor (ER), we studied the in vitro metabolism of [(3)H]-labeled NET in cultured neonatal rat osteoblasts and the interaction of its metabolic conversion products with cytosolic -osteoblast ER, employing a competition analysis. Results indicated that NET was extensively bioconverted (36.4%) to 5 alpha-reduced metabolites, including 5 alpha-dihydro NET, 3 alpha,5 alpha-tetrahydro NET (3 alpha,5 alpha-NET) and 3beta,5 alpha-tetrahydro NET (3beta,5 alpha-NET), demonstrating the activities of 5 alpha-steroid reductase and two enzymes of the aldo-keto reductases family. Expression of Srd5a1 in neonatal osteoblast was well demonstrated, whereas Srd5a2 expression was not detected. The most striking finding was that 3beta,5 alpha-NET and 3 alpha,5 alpha-NET were efficient competitors of [(3)H]-estradiol for osteoblast ER binding sites, exhibiting affinities similar to that of estradiol. The results support the concept that the interplay of 5 alpha-steroid reductase and aldo-keto reductases in osteoblastic cells, acting as an intracrine modulator system is capable to bioconvert a PR agonist into ER agonists, offering an explanation of the molecular mechanisms NET uses to enhance osteoblastic cell activities.

Biophysical evidence that connexin-36 forms functional gap junction channels between pancreatic mouse beta-cells.

Connexin-36 (Cx36) is the only gap junction protein that has been unambiguously identified in rodent pancreatic beta-cells. However, properties of gap junction channel unitary currents between beta-cells remain unrevealed. To address whether Cx36 forms functional channels in beta-cells, we characterized biophysical properties of macro- and microscopic junctional currents recorded from dual whole cell voltage clamp isolated pairs of dispersed mouse beta-cells. Electrical coupling was recorded in 80% of cell pairs with a junctional conductance (g(j)) of 355 +/- 45 pS (n = 20). Transjunctional voltage dependence was identified in three of seven cell pairs with high-input membrane resistances. Normalized steady-state g(j) (Gj) and transjunctional-voltage relation were well described by a two-state Boltzmann equation [maximal conductance (Gmax) = 1.0, voltage-insensitive conductance (Gmin) = 0.3 and 0.28, voltage gating sensitivity (A) = 0.21 and 0.23, and voltage at which one-half of the initial voltage-dependent conductance was reached (Vo) = -85 and 87 mV for negative and positive potentials, respectively]. Halothane reversibly uncoupled beta-cell pairs, and, during recovery, unitary conductances of 5-10 pS were recorded while using patch pipettes containing mainly CsCl. Although these properties are similar to those previously described for Cx36 channels in mammalian cell systems, we found that beta-cell junctional currents were insensitive to quinine. Cx36 transcript and protein expression in islets and freshly dispersed cell preparations was confirmed by RT-PCR and immunofluorescence. In conclusion, biophysical properties of junctional channels between beta-cells are similar but not identical to those previously described for homomeric Cx36 channels. Cell type-specific mechanisms that may account for these differences are discussed.

Implementation and evaluation of a national external quality control program for cervical cytology in Mexico.

OBJECTIVE: To evaluate cytology laboratories and the performance of cytotechnologists for establishing efficient external quality control for Mexico's National Program for the Prevention and Control of Cervical Cancer. MATERIAL AND METHODS: During January and February 1998, an onsite evaluation of all cytology laboratories of the Ministry of Health found that only 70% of the microscopes were in adequate working conditions, reagents were out of date, and working conditions were sub-optimal. A program for external quality control based on proficiency testing was established for cytotechnologists. Fifty slide sets with 20 Papanicolaou slides and 10 photographic slides were prepared. The sets were given to the cytotechnologists for evaluation and again one year later by courier. RESULTS: Twenty-one percent of microscopes were repaired and 9% replaced; reagents were distributed and laboratory facilities improved. Only 16% of cytotechnologists passed the initial proficiency test. Cytotechnologists received a refresher training course: one year later 67% of them passed the proficiency test. To ascertain that each slide was correctly diagnosed, 41 sets were rescreened by expert cytopathologists or cytologists and their diagnoses compared to the original ones. Thirty-seven sets had 86% to 96% concordance. CONCLUSIONS: This new system for external quality control of cervical cytology allowed the opportune and reliable evaluation of the performance of cytotechnologists.

A monoclonal antibody driven biodiagnostic system for the quantitative screening of breast cancer.

A prospective clinical parametric study comprising women afflicted by breast cancer and otherwise healthy participants was undertaken. The mean plasmatic concentration of putative leucine amino peptidase and nucleoside diphosphate phosphotransferase enzymatic complex in breast cancer cases was significantly elevated [43.9 +/- 2.8 microg ml(-1) (n = 9)] when compared to those found in otherwise healthy women [8.07 +/- 0.14 microg ml(-1) (n = 8)]. Women without images compatible with any tumours (n = 13) had a mean concentration of 10.77 +/- 1.49 microg ml(-1). The mean value obtained in women with fibroadenomas was 10.15 +/- 0.81 microg ml(-1) (n = 6) and with cystic fibrosis mastopathy 8.75 +/- 0.28 microg ml(-1) (n = 7). The efficacy of a tandem quantitative biodiagnostic system as a parametric screening tool for the early detection of breast cancer is underlined, raising the possibility of increasing the cost effectiveness of current imaging non-parametric technologies.

Sertoli cell only syndrome: a variant of testicular germinal cell abscence

Con el objeto de estudiar el valor diagnóstico de la biopsia testicular n el Síndrome de las Células de Sertoli (SCS), se analizaron 70 biopsias de testículo obtenidas de pacientes que acudieron a una clínica de infertilidad. Los hallazgos morfológicos se correlacionaron con los datos clínicos, análisis del semen y perfil hormonal. Aún cuando catorce casos reunieron los criterios histológicos de ausencia de células germinales, los estudios de correlación revelaron que únicamente 8 de ellos presentaban las características clínicas y hormonales descritas originalmente para el SCS, incluyendo desarrollo sexual masculino normal, infertilidad primaria, azoospermia, concentraciones elevadas de FSH y normales o discretamente elevadas de LH en suero y testosterona normal. Los seis casos restantes mostraban características clínicas y endocrinológicas compatibles con otras causas de daño ubular incluyendo hipogonadismo hipogonadotrópico de origen suprahipofisiario. Síndrome de Noonan, deficiencia testicular de 17-oxoesteroide reductasa y daño tubular por agentes alkilantes. Los resultados de este análisis demuestran que para integrar el diagnóstico preciso del SCS se requiere del análisis detallado de las anormalidades morfológicas y hormonales y de aquellas obtenidas del estudio clínico

La progesterona y sus metabolitos en el funcionamiento del sistema nervioso central / Progesterone and its metabolites the functions of the central nervous system

La progesterona (P4) y sus metabolitos participan en distintas funciones del sistema nervioso central (SNC) entre las que destacan la excitabilidad neuronal, la reproducción, y las conductas asociadas a ésta. P4 y sus metabolitos actúan en las neuronas y en las células gliales a través de su interacción con: 1) receptores intracelulares específicos; 2) sitio de regulación presentes en los receptores a neurotransmisores; y 3) canales iónicos. Por estos mecanismos se inducen cambios en la expresión de genes específicos, la formación de segundos mensajeros y la conductancia iónica. La mayoría de las acciones de los metabolitos de P4 en el SNC, ocurren a nivel membranal, mientras que las de P4 son principalmente a nivel nuclear y están mediadas por la activación de los receptores intracelulares. Así, P4 y sus metabolitos pueden modificar el funcionamiento de distintas regiones del SNC, a corto (milisegundos), mediano (minutos) y largo plazo (horas y días). El conocimiento de los mecanismos moleculares por los cuales P4 y sus metabolitos participaron en el funcionamiento del SNC, permitirá entender procesos biológicos fundamentales como la conducta sexual y la reproducción; además, contribuirá al diseño de terapias alternativas en el tratamiento de diferentes trastornos neurológicos y psiquiátricos como la epilepsia, la ansiedad, el síndrome premenstrual y algunos tumores cerebrales que tienen regulación hormonal

Anticoncepción postaborto / Postpartum anticonception

El embarazo incrementa el riesgo de eventos isquémicos cerebrovasculares. La trombosis del seno longitudinal es muy rara, pero la incidencia aumenta en el embarazo y el puerperio. La mortalidad es de 25 a 50 por ciento, se presenta un caso estudiado y maneja en el Hospital Central Militar. Se presentó durante el décimosegundo día postcesárea; en diagnosticó se corroboró con estudio de Resonancia Magnética Nuclear, se trató a base de heparina y reposo, evaluacionando satisfactoriamente. Lo cual coincide con estudios retrospectivos recientes que sugieren que existe un efecto benéfico con el uso de heparina, disminuyendo drásticamente la mortalidad. Aunque existen investigadores que se oponen por la posibilidad de hemorragia intracraneana

Comportamiento de la cesárea en la SSA durante el período 1990-95 / Cesarean section characteristics at the Ministery of Health from 1990 to 1995

Se analizó el comportamiento de la operación cesárea en la Secretaría de Salud (SSA), durante el período 1990-95 y establecer su relación con la mortalidad materna y perinatal. Se realizó un estudio descriptivo basado en la información sobre cesáreas informadas por el Sistema Estatal de Información Básica (SIB) y en la información sobre mortalidad materna y perinatal informada por los Comités Intrahospitalarios de la SSA, durante el periodo 1990-95. Esta información se analizó como serie cronológica, para analizar los cambios en las tasas anuales de esta operación, tanto a nivel nacional como por entidades federativas. Se utilizó la prueba estadística de Pearson para determinar la correlación existente entre la frecuencia de cesáreas y la mortalidad materna y perinatal en igual período. El nivel de confianza utilizado fue de 95 por ciento (p<0.05). La frecuencia de cesáreas en la SSA se presentó como un fenómeno de evolución creciente y fue también creciente al considerar las entidades federativas por separado. Se observó una correlación positiva y estadísticamente significativa entre la frecuencia de cesáreas y la mortalidad materna, mientras que el aumento en la frecuencia de cesáreas no guardó relación con la mortalidad perinatal. El incremento de las cesáreas en la SSA durante el período analizado, estuvo más allá de los límites de sus beneficios y pudo haber contribuido a aumentar la morbilidad y mortalidad materna y los costos hospitalarios. Este aumento resulta preocupante debido a que la tendencia en la frecuencia de esta operación es seguir aumentando en los próximos años, si no se realizan acciones concretas y rápidas para disminuir la misma

Heterogeneidad bioquímica y endocrina en la forma completa del síndrome de feminización testicular / Biochemical and endocrine heterogeneity in the complete form of the testicular feminization syndrome

Se estudió una variante familiar de pseudohermafroditismo masculino endocrinológicamente diferente al de la forma clásica del síndrome de feminización testicular completa (STFC). Los tres sujetos afectados, con complemento cromosómico 46 XY y edades de 16, 18 y 20 años, presentaban un fenotipo femenino idéntico al de un paciente de 17 años de edad con la forma clásica del SFTC incluido en el estudio con fines comparativos. Las mayores diferencias endocrinas y bioquímicas encontradas en esta familia, comparadas con la forma clásica fueron: a. elevadas concentraciones de gonadotropinas en el suero sanguíneo; b. testosterona en suero en límites inferiores; c. pobre respuesta testicular a la administración de gonadotropina coriónica; d. relación testosterona: androstendiona anormalmente disminuida; e. leve respuesta hipotálamo-hipofisiaria a la administración de andrógenos; f. existencia de capacidad residual para captar y retener andrógenos en forma intracelular. Estas diferencias, con excepción de la e, fueron más evidentes en los pacientes de 18 y 20 años. Todos los sujetos fueron incapaces de retener nitrógeno en forma significativa durante la administración de testosterona. Las relaciones testosterona: androstendiona anormales sugieren disminución parcial secundaria de la enzima 17-hidroxiesteroide deshidrogenasa, tal y como ha sido demostrado en los modelos del SFTC del roedor. Los resultados en conjunto son indicativos de la existencia de variabilidad en la expresión de la insensibilidad a los andrógenos dependiente de la edad, así como de una amplia heterogeneidad bioquímica y endocrinológica en este síndrome

Estudios clínicos, citogenéticos, endocrinológicos e histológicos en hermafroditas verdaderos / Clinical, cytogenetic, endocrinologic and histologic studies in true hermaphroditism

En el presente trabajo se describen los hallazgos clínicos, citogenéticos, endocrinológicos e histológicos en nueve pacientes mexicanos con hermafroditismo verdadero. La edad de los pacientes, a su ingreso, se encontraba entre los 10 meses y los 27 años; en siete casos el sexo de asignación era masculino, siendo el cariotipo más frecuente 46,XX (n=6). Las concentraciones basales de gonadotropinas y esteroides gonadales variaron de acuerdo con la edad del sujeto, tipo de gónada y estado funcional de la misma aunque la funcionalidad del tejido ovárico siempre fue superior a la del tejido testicular. La respuesta de testosterona al estímulo con HCG también fue variable. En un sujeto con hematuria cíclica se logró detectar ovulación expontánea. La gónada más frecuentemente encontrada fue el ovotestes siendo bilateral en cuatro casos; los genitales internos variaron dependiendo del tipo de gónada presente; en los nueve casos se documentó la presencia de útero. Los hallazgos previamente descritos concuerdan con lo reportado en individuos con hermafroditismo verdadero en otras poblaciones.

Pubertad precoz isosexual secundaria a quiste subaracnoideo / Isosexual precocious puberty due to subarachnoid cyst

Se describe un nuevo caso de pubertad precoz verdadera isosexual secundaria a la presencia de un quiste subaracnoideo en una niña de 16 meses de edad. El motivo de la consulta fue haber presentado dos episodios de sangrado endometrial. Los resultados endocrinológicos demostraron actividad del eje hipotálamo-hipófisis-ovario, mientras que la arteriografía y la tomografía axial computada de cráneo evidenciaron la presencia de un quiste subaracnoideo de gran tamaño. La resección quirúrgica de la mayor parte del quiste, con la colocación de una válvula de derivación, no fue suficiente para suprimir la actividad hormonal, por lo que fue necesario instituir tratamiento supresivo a base de acetato de medroxiprogesterona con lo que se ha logrado detener el proceso puberal